Dentons and Latham & Watkins advised ATAI Life Sciences on the deal. ATAI Life Sciences closed a $125 million Series C financing round. Founding investor Apeiron…
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
